Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

FEI announces final decision in banned substance case
Horse racing
During the FEI tribunal, Dr Kamaal admitted that he had administered Fustex, a product that contains Propxyphene.
Staff member administered product containing Propoxyphene

A two-year suspension has been imposed on Dr Pasha Syed Kamaal after a banned substance was detected at a UAE event, the FEI has confirmed.

Dr Kamaal was identified as a member of support staff in a 2012 equine anti-doping case which involved a horse ridden by HH Sheik Hazza.

Samples taken from the horse returned positive for the banned substance Propoxyphene, an opioid analgesic, and its metabolite Norpropoxyphene.

In addition to a two-year suspension, Dr Kamaal has also received a fine of CHF 2,500 and costs of CHF 1,000.

Previously, the FEI imposed a 27-month suspension on HH Sheikh Hazza as the person responsible, but this was reduced to 18 months following an appeal to the Court of Arbitration for Sport.

During the FEI tribunal, Dr Kamaal admitted that he had administered Fustex, an Argentinian product, to the horse the night before the event.

Used to promote muscle growth, Fustex contains Propoxyphene but it is not yet listed as an ingredient.

The FEI has since issued a statement to stakeholders urging caution over the use of Fustex. They warn that lack of knowledge is no valid excuse in any anti-doping procedures. 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.